EGR3 and prostate cancer: Similarly, in hepatocellular carcinoma [16], canine mammary cancer [17], and prostate cancer [18], EGR3 appears to inhibit growth and metastasis, often through suppression of the epithelial–mesenchymal transition or induction of apoptosis-related pathways.